COVID-19 Booster Vaccination in Persons With Multiple Sclerosis

November 16, 2022 updated by: Griffin Hospital
The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the immune system do not produce neutralizing antibodies to COVID-19 proteins in response to vaccination. This group includes a significant number of persons with multiple sclerosis (PWMS), many of whom are on therapies that chronically suppress their immune function. It is unclear what advice clinicians should provide regarding COVID-19 precautions to patients who fail to develop detectable COVID-19 spike protein antibodies using standard commercially-available tests after a standard series of vaccination, or whether they should test for antibody responses to COVID-19 vaccines in the absence of guidelines. A key research question is whether, in the absence of stopping or reducing potentially immune-altering therapies, there is a way to increase the likelihood of a neutralizing antibody response to COVID-19 vaccination in PWMS who are taking immune suppressive medications.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

The goal of this study is to test whether adding booster doses of COVID-19 vaccine to PWMS can improve the immune response to COVID-19.

Specific Aims:

  • To compare pre and post anti-COVID-19 immunity after a booster vaccination in PWMS who initially test negative for neutralizing antibodies to COVID-19 after initial vaccination;
  • To determine how disease modifying treatments, baseline antibody panels and lymphocyte subsets associate with the efficacy of booster vaccines;
  • To compare immune responses between homologous vs. heterologous booster vaccination.

Research Implications:

It is hoped that the results of this study will help guide clinical recommendations on the use of booster vaccination and whether to endorse heterologous versus homologous boosters. It is also hoped that this study will add to the growing body of data on COVID-19 immunity after vaccination in PWMS on various disease modifying treatments (DMTs).

Hypotheses:

  • Booster doses of COVID-19 vaccines will improve antibody-based immunity to COVID-19in PWMS who initially test negative for neutralizing antibodies to COVID-19 after initial vaccination;
  • This boost in immunity will occur irrespective of disease modifying therapy (DMT);
  • Heterologous prime-boost combinations will show greater immune responses than homologous prime-boost combinations.

Background:

Multiple Sclerosis (MS) is an autoimmune condition associated with focal inflammatory infiltrates in the brain consisting of T and B lymphocytes, macrophages and activated microglial cells, with the principal target being the myelin sheath of central nervous system (CNS) axons. The approach to treating MS involves disease-modifying therapies (DMT) that have the effect of reducing access of potentially myelin-autoreactive immune cells to the CNS compartment. These treatments are shown to reduce exacerbations of disease and, to some degree, delay progression of neurological disability, both by clinical assessment, and, by the best surrogate marker to date, magnetic resonance imaging of the brain.

DMTs used to treat MS target adaptive immune responses in various ways. These include medications that shift cytokine and lymphocyte subsets towards less inflammatory activity, interfere with trafficking of lymphocytes in the circulation or central nervous system, or otherwise inhibit lymphocytes through nonspecific or subset depletion.

Approved and off-label treatments for MS include:

  1. anti-CD20 (CD20 is a B lymphocyte receptor) monoclonal antibodies (ocrelizumab, rituximab and ofatunumab);
  2. lymphocyte-sequestering drugs (fingolimod, onzanimod, siponomod);
  3. adhesion molecule antibodies that prevent CNS lymphocyte trafficking(natalizumab);
  4. nuclear erythroid 2-related factor two (Nrf2) modulators (dimethyl fumarate, diroxmel fumarate);
  5. nonselective lymphocyte-depleters (cyclophosphamide, cladribine, alemtuzumab);
  6. replication blocking lymphostatic drugs (teriflunomide) and immune modulators (interferon, glatiramer acetate).

All of these mechanisms could, theoretically, influence immune responses to vaccination. Live or live attenuated vaccines are contraindicated with several DMTs due to the risk of immune suppression. For COVID-19 immunity, both B and T lymphocyte activation is important. DMTs that are more immune-suppressive have shown attenuated responses to influenza vaccines and, presumably, would show the same for COVID-19 vaccines. These include the lymphocyte-sequestering drugs (e.g., fingolimod, onzanimod and siponimod), the antiCd20+ depleting drugs (e.g., ocrelizumab, ofatunumab and rituximab), and the general immune suppressants (e.g., alemtuzumab or cladribine). DMTs that have not been shown to inhibit immune responses to influenza vaccines include the interferons, glatiramer acetate, dimethyl fumarates, diroximel, and teriflunomide.

Currently three COVID-19 vaccines in the U.S. have either been approved for use or granted Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). BNT162b2, manufactured by Pfizer, Inc. and BioNTech, Inc. and mRNA-1273, manufactured by Moderna, Inc., are RNA-based vaccines. They consist of modified COVID-19 mRNA sequences for the receptor-binding domain (RBD) of the M-spike protein. The mRNAs enter host cells via a lipid nanoparticle delivery system, where they are transcribed by host cell enzymes to produce a stabilized prefusion SARS-CoV-2 spike protein (S-2P), which localizes to the cell surface and presented as antigen for the host immune system. Ad26.COV2.S, manufactured by Johnson & Johnson/Janssen, is a dsDNA vaccine that employs a similar strategy, the difference being that it enters the host cell nucleus via a non-replicating adenovirus vector, where it is transcribed to make spike protein.

In some literature reviews and studies, PWMS, including those on a wide spectrum of DMTs, do not seem to be at greater risk per se of increased morbidity and mortality from COVID-19 infection. A review of 873 published cases of COVID-19 multiple sclerosis patients, found that the overall mortality rate was 4% and that an additional 3% required some form of ventilation. Furthermore, immune suppressive treatments did not appear to be a risk factor for severe disease. An unfavorable prognosis for 28 PWMS who contracted COVID-19 in a Spanish study was related to older age and greater disability. These and other observations have prompted some to speculate that relative immune suppression may actually protect PWMS against inflammatory storm that accompanies severe COVID-19 infection. On the other hand, a meta-analysis of 84 reports of PWMS with COVID-19 infection and their DMT treatments, while not finding a relationship between the type of DMT and COVID-19 course, did find that the highest mortality rate, e.g., 4% out of a 1.8% overall mortality rate of those infected, was in persons treated with rituximab, a monoclonal antibody that suppresses B lymphocytes and antibody production. This higher incidence of severe COVID-19 infection in MS patients on rituximab was confirmed by another retrospective study. A similar monoclonal antibody, ocrelizumab, was found to be associated with suppressed COVID-19 specific antibodies compared to other DMTs among 59 PWMS who had laboratory-confirmed COVID-19 infection. However, COVID-19 specific T lymphocyte assays were not different between ocrelizumab and other DMTs.

While there is a paucity of data relating to MS, DMTs and acquired immunity to COVID-19 infection, there is evidence that the use of some DMTs in MS can attenuate the immune response to various viral and nonviral vaccines. A number of DMTs in common use in MS patients increase their risk for a number of infectious complications, including bacterial and nonbacterial upper and lower respiratory tract infections, herpes virus infections, cryptococcal meningitis, progressive multifocal leukoencephalopathy and reactivation of latent tuberculosis and hepatitis B infections. Therefore, clinicians must be mindful of the initiation and timing of vaccinations, as well as the selection of DMTs in particular patients, to mitigate the risk of opportunistic infections.

This is critical with respect to assessing the protective effect of COVID-19 vaccination during the pandemic, especially as public health measures against COVID-19, e.g., social distancing, mask wearing, work and school restrictions, have been relaxed for vaccinated persons. What is clear from some preliminary studies is that PWMS on particular DMTs have attenuated responses to COVID-19 vaccines. Furthermore, there are approximately a dozen ongoing studies assessing the impact of DMTs on COVID-19 vaccination. One such study looked at antibody levels to the COVID-19 spike protein after vaccination with BNT162b2 in patients on no treatment or high efficacy DMTs, e.g., fingolimod, cladribine, or ocrelizumab. Humoral immunity in patients on ocrelizumab was achieved in 22.7%; fingolimod 3.8%, and cladribine 100% 33.

The potential attenuation of immunity to COVID-19 vaccination in PWMS at present is an unresolved dilemma for patients and physicians. Of course, this applies to other patients as well, including those on immune suppressive treatments for cancer or rheumatological diseases. There are commercially available assays to measure COVID-19 spike protein antibodies, but what are physicians to tell patients who test negative for these antibodies after vaccination. Some MS colleagues take the position that the tests should not be ordered due to a lack of guidance as to how to use that information.

One possible way to mitigate this dilemma is to administer booster vaccinations. A number of clinical investigators in other medical specialties are testing this approach. Indeed, since the extent to which the current vaccines induce long-term immunity to COVID-19 ia unknoqn, this is a relevant issue for the general population as well. A small study of 33 adults showed that high levels of antibodies persisted for six months after vaccination with mRNA-1273.

A booster vaccine may be homologous (same vaccine) or heterologous (different vaccine) relative to the initial vaccine. Evidence from one mouse study indicates that the immune response is more robust from heterologous combinations of mRNA and DNA COVID-19 vaccines than homologous combinations, particularly in the induction of T cells, which is believed to be more important for long term immunity. Another rationale for the use of heterologous combinations is to administer one dose each of the combination, rather than a full series of the mRNA vaccine, to determine which strategy produces more robust immunity.

This study will attempt to address whether giving a heterologous dose of a booster vaccine will increase the chance of both antibody production and T lymphocyte activation in PWMS who do not initially show evidence of antibody reactivity.

Research Plan:

The research team will recruit PWMS who have completed vaccination against COVID-19 and test negative for COVID-19 spike protein antibodies using a commercial assay. Subjects will have baseline blood drawn for T and B lymphocyte subsets, quantitative immune globulins and COVID-19 spike protein antibodies. Women of child-bearing potential will have a urine pregnancy test. Baseline, demographic and disease specific variables will be collected.

Subjects will be randomized on a stratified basis to one of two treatment groups: Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. Depending on the initial vaccine series received, this means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa.

Subjects will return to the clinic 4 to 6 weeks later to be retested for COVID-19 spike protein antibodies. Reactions to the booster vaccine and any potential adverse events will be recorded.

Visit 1:

  • Clinical screening; review of clinical course; medications; body mass index; vital signs; physical exam, neurological exam; and urine pregnancy test (if applicable);
  • Phlebotomy for B and T lymphocyte subsets, quantitative immune globulins and COVID-19 spike antibodies;
  • Administration of vaccine, followed by monitoring for any adverse effects for 15 to 30 minutes.

Visit 2:

  • Physical and neurological examination
  • Change of medications, assessment of disease activity (including relapses), adverse events including an assessment of relationship to vaccination
  • Phlebotomy for COVID-19 spike protein antibodies

Data Analysis:

  • Spike protein antibody titers, quantitative immune globulins, B & T cell subsets and COVID-specific T lymphocytes will be analyzed between Groups 1 & 2 and within Groups 1 & 2.
  • DMT treatment, prior COVID-19 and/or vaccination history will be treated as covariates.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Connecticut
      • Derby, Connecticut, United States, 06418
        • Griffin Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Diagnosis of clinically definite multiple sclerosis (CDMS) by the 2017 McDonald Criteria 38;
  2. Age greater than or equal to 18 years;
  3. Ability to travel to Griffin Hospital for phlebotomy and booster vaccination;
  4. Completion of an initial COVID-19 vaccine series at least 4 weeks prior to booster randomization (i.e., two doses of either BNT162b2 or mRNA-1273, or one dose of Ad26.COV2.S);
  5. Prior negative test for COVID-19 spike protein antibodies using a commercial assay;
  6. Willing to undergo a booster vaccination with either BNT162b2, mRNA-1273 or Ad26.COV2.S.

Exclusion Criteria:

  1. Inability to give consent;
  2. Non-fluency in English;
  3. Inability to adhere to the protocol;
  4. Anticipated life expectancy of less than six months;
  5. Lack of a primary care physician or treating neurologist;
  6. Taking an immunosuppressive medication or chemotherapy for any other conditions aside fromMS;
  7. Presence of another autoimmune condition requiring treatment;
  8. Active treatment for cancer;

  9. History of heavy alcohol use within the past year, as defined by the following criteria:

    1. Men: 5 or more alcoholic beverages per session or per day, or 15 or more per week;
    2. Women: 4 or more alcoholic beverages per session or per day, or 8 or more per week;
  10. History of illicit drug abuse, e.g., cocaine, heroin, PCP, and/or narcotics within the past year;
  11. Any condition that would jeopardize the safety or rights of the subject, make it unlikely for the subject to complete the study, or confound the study results.
  12. Anaphylactic or other severe reaction to a previously administered COVID-19 vaccine;
  13. MS relapse or worsening symptoms after initial COVID-19 vaccination.
  14. Positive urine pregnancy test at screening [women only]. Test is waived in women who are post-menopausal or incapable of conception.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Homologous booster vaccine group
A single dose booster of the same type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
Biological: Homologous booster
Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
Active Comparator: Heterologous booster vaccine group
A single dose booster of the opposite type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
Biological: Heterologous booster
Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent who test positive for COVID-19 spike protein antibodies following booster
Time Frame: 4-6 weeks
Percentage of subjects who test positive for COVID-19 spike protein antibodies following a booster vaccination.
4-6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of COVID-19 spike protein antibodies based on booster received
Time Frame: 4-6 weeks
Comparison of percentage of subjects who test positive for COVID-19 specific spike protein antibodies between those who receive homologous vs. heterologous boosters from baseline;
4-6 weeks
Comparison of COVID-19 spike protein antibodies based on disease-modifying treatment
Time Frame: 4-6 weeks
Comparison of percentage of subjects who test positive for COVID-19 spike protein antibodies based on disease modifying treatment;
4-6 weeks
Correlation of COVID-19 spike protein antibodies with B and T cell levels and immunoglobulins
Time Frame: 4-6 weeks
Correlation of COVID-19 spike antibody presence and levels based on B and T cell subsets and overall immune globulin levels.
4-6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Griffin Hospital

Collaborators

Yale-Griffin Prevention Research Center
Multiple Sclerosis Treatment Center

Investigators

  • Principal Investigator: Joseph B Guarnaccia, MD, Griffin Hospital
  • Principal Investigator: Frederick Browne, MD, Griffin Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2021

Primary Completion (Actual)

May 30, 2022

Study Completion (Actual)

May 30, 2022

Study Registration Dates

First Submitted

October 14, 2021

First Submitted That Met QC Criteria

October 14, 2021

First Posted (Actual)

October 18, 2021

Study Record Updates

Last Update Posted (Actual)

November 21, 2022

Last Update Submitted That Met QC Criteria

November 16, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-12

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

De-identified requests for IPD that underlie results in a publication will be made available to other researchers upon requests sent to the study PI.

IPD Sharing Time Frame

IPD will be shared upon request following publication of our findings.

IPD Sharing Access Criteria

The study PI will review and address requests for IPD.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Informed Consent Form (ICF)
  • Clinical Study Report (CSR)
  • Analytic Code

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on Homologous booster

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe